Tuesday, August 9, 2022 | Back issues
Courthouse News Service Courthouse News Service

Pharma Merger

WILMINGTON, Del. - Directors are selling Ambit Biosciences too cheaply through an unfair process to Daiichi Sankyo, for $15 a share or $410 million, shareholders claim in a class action in Chancery Court.

Read the Top 8

Sign up for the Top 8, a roundup of the day's top stories delivered directly to your inbox Monday through Friday.